Yuhan Strikes Long-Awaited Lung Cancer Deal Through Huge Janssen Alliance

License agreement
Click here to view original web page at scrip.pharmaintelligence.informa.com

License agreement

Executive Summary

Yuhan inks long-awaited, major global license agreement for its novel third-generation EGFR TKI with Janssen, in a $1.2bn deal poised to boost the South Korean firm's ongoing R&D efforts in key therapeutic areas, while Janssen will further beef up its oncology portfolio. But competition with entrenched rival Tagrisso awaits.

Register for our free email digests:

License agreement
Yuhan Licenses Out Novel EGFR-TKI To Janssen

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.